NCT01144195View on ClinicalTrials.gov

A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2011

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Panitumumab + FOLFIRI

Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.

Trial Locations (1)

08021

Associació Catalana per la Recerca Oncològica i les Seves Implicacions Sanitaries i Socials, Barcelona